On December 14, Heyuan Biotech (688238.SH) said on an interactive platform that, as a leading domestic company that lays out gene and cell therapy, Heyuan Biotech has accumulated rich project experience in gene and cell therapy drug development with a large number of product development experience, advanced processes and production capacity, a high standard quality system, and a high-level technical service team, and has accumulated rich project experience in gene and cell therapy drug development, providing high-quality CRO/CDMO services for new drug projects in various fields such as oncolytic viruses, adenoviruses, lentiviruses, mRNA plasmids, CART, stem cells, NK cells, etc. At present, we have collaborated on more than 280 CDMO projects in China, supported customers to obtain 30+ domestic and foreign IND approvals, and continuously accelerate the R&D, clinical and commercialization process of project products.